Eirini D Tseligka1, Aikaterini Rova1, Elsa P Amanatiadou1, Gianpiero Calabrese2, John Tsibouklis3, Dimitrios G Fatouros4, Ioannis S Vizirianakis5,6. 1. Department of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. 2. School of Pharmacy and Chemistry, Kingston University, Kingston-upon Thames, KT1 2EE, UK. 3. School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2DT, UK. 4. Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. 5. Department of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. ivizir@pharm.auth.gr. 6. Department of Life and Health Sciences, University of Nicosia, 1700, Nicosia, Cyprus. ivizir@pharm.auth.gr.
Abstract
PURPOSE: Tumor cell heterogeneity and microenvironment represent major hindering factors in the clinical setting toward achieving the desired selectivity and specificity to malignant tissues for molecularly targeted cancer therapeutics. In this study, the cellular and molecular evaluation of several delocalized lipophilic cation (DLC)-functionalized carborane compounds as innovative anticancer agents is presented. METHODS: The anticancer potential assessment of the DLC-carboranes was performed in established normal (MRC-5, Vero), cancer (U-87 MG, HSC-3) and primary glioblastoma cancer stem (EGFR(pos), EGFR(neg)) cultures. Moreover, the molecular mechanism of action underlying their pharmacological response is also analyzed. RESULTS: The pharmacological anticancer profile of DLC-functionalized carboranes is characterized by: a) a marked in vitro selectivity, due to lower concentration range needed (ca. 10 fold) to exert their cell growth-arrest effect on U-87 MG and HSC-3, as compared with that on MRC-5 and Vero; b) a similar selective growth inhibition behavior towards EGFR(pos) and EGFR(neg) cultures (>10 fold difference in potency) without, however, the activation of apoptosis in cultures; c) notably, in marked contrast to cancer cells, normal cells are capable of recapitulating their full proliferation potential following exposure to DLC-carboranes; and, d) such pharmacological effects of DLC-carboranes has been unveiled to be elicited at the molecular level through activation of the p53/p21 axis. CONCLUSIONS: Overall, the data presented in this work indicates the potential of the DLC-functionalized carboranes to act as new selective anticancer therapeutics that may be used autonomously or in therapies involving radiation with thermal neutrons. Importantly, such bifunctional capacity may be beneficial in cancer therapy.
PURPOSE: Tumor cell heterogeneity and microenvironment represent major hindering factors in the clinical setting toward achieving the desired selectivity and specificity to malignant tissues for molecularly targeted cancer therapeutics. In this study, the cellular and molecular evaluation of several delocalized lipophilic cation (DLC)-functionalized carborane compounds as innovative anticancer agents is presented. METHODS: The anticancer potential assessment of the DLC-carboranes was performed in established normal (MRC-5, Vero), cancer (U-87 MG, HSC-3) and primary glioblastoma cancer stem (EGFR(pos), EGFR(neg)) cultures. Moreover, the molecular mechanism of action underlying their pharmacological response is also analyzed. RESULTS: The pharmacological anticancer profile of DLC-functionalized carboranes is characterized by: a) a marked in vitro selectivity, due to lower concentration range needed (ca. 10 fold) to exert their cell growth-arrest effect on U-87 MG and HSC-3, as compared with that on MRC-5 and Vero; b) a similar selective growth inhibition behavior towards EGFR(pos) and EGFR(neg) cultures (>10 fold difference in potency) without, however, the activation of apoptosis in cultures; c) notably, in marked contrast to cancer cells, normal cells are capable of recapitulating their full proliferation potential following exposure to DLC-carboranes; and, d) such pharmacological effects of DLC-carboranes has been unveiled to be elicited at the molecular level through activation of the p53/p21 axis. CONCLUSIONS: Overall, the data presented in this work indicates the potential of the DLC-functionalized carboranes to act as new selective anticancer therapeutics that may be used autonomously or in therapies involving radiation with thermal neutrons. Importantly, such bifunctional capacity may be beneficial in cancer therapy.
Entities:
Keywords:
DLC-carboranes; anticancer therapeutics; cancer cells; normal cells; p53/p21 axis
Authors: Charla C Engels; Francesca Ruberta; Esther M de Kruijf; Gabi W van Pelt; Vincent T H B M Smit; Gerrit Jan Liefers; Tomoko Matsushima; Masaki Shibayama; Hideki Ishihara; Cornelis J H van de Velde; Peter J K Kuppen Journal: Breast Cancer Res Treat Date: 2013-11-06 Impact factor: 4.872
Authors: Neha Parikh; Susan Hilsenbeck; Chad J Creighton; Tajhal Dayaram; Ryan Shuck; Eve Shinbrot; Liu Xi; Richard A Gibbs; David A Wheeler; Lawrence A Donehower Journal: J Pathol Date: 2014-01-29 Impact factor: 7.996
Authors: Volodymyr Horishny; Athina Geronikaki; Victor Kartsev; Vasyl Matiychuk; Anthi Petrou; Pavel Pogodin; Vladimir Poroikov; Theodora A Papadopoulou; Ioannis S Vizirianakis; Marina Kostic; Marija Ivanov; Marina Sokovic Journal: Molecules Date: 2022-02-05 Impact factor: 4.411